RIT with 90Y-rituximab in CD20+ B-cell lymphoma has shown promising efficacy and tolerability when utilizing the 90Y-ibritumomab tiuxetan schedule [10]. Here, MS4A1 is linked to B-cell non-Hodgkin lymphoma.